Former Chief Financial Officer · Black Diamond Therapeutics, Inc. (BDTX)

Thomas Leggett

FY2021 is the first fiscal year CompBrief holds for Thomas Leggett as a named executive officer of Black Diamond Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,856,183

Salary $381,885Stock awards $0

3rd of 4 named executive officers at Black Diamond Therapeutics by FY2021 total.

4 named officers on file for Black Diamond Therapeutics, FY2021

Thomas Leggett’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Black Diamond Therapeutics’s whole pay program stands against its peers

  • Black Diamond Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on BDTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2022 (DEF 14A).

Free

Get Thomas Leggett’s full pay file as a PDF — free

More than this page: up to 10 years of Thomas’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Thomas Leggett compensation by year

Black Diamond Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Black Diamond Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$381,885
Bonus$0
Stock awards$0
Option awards$1,411,832
Non-equity incentive$0
Pension and deferred compensation$0
All other$62,466
Total$1,856,183

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Black Diamond Therapeutics, Inc. DEF 14A filed April 28, 2022, accession 0001104659-22-052245, and prior-year filings.

How this page was built: the Black Diamond Therapeutics, Inc. filed document, accession 0001104659-22-052245. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.

Black Diamond Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
David EpsteinPresident and Chief Executive Officer$5,090,225
Brent Hatzis-SchochChief Operating Officer, General Counsel$2,022,309
Thomas Leggett · this pageFormer Chief Financial Officer$1,856,183
Fang NiChief Business Officer and Interim Chief Financial Officer$1,674,570

The full Black Diamond Therapeutics compensation record

free company brief

This page is one person within Black Diamond Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Black Diamond Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Thomas Leggett's compensation dossier · One-time report. No refunds.